CD47 Inhibitor

CD47 Inhibitors (31):

Cat. No.	Product Name	Effect	Purity

HY-P99029

Magrolimab	Inhibitor	99.92%
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer.

HY-16438

RRx-001	Inhibitor	99.79%
RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity.

HY-P99172

CC-90002	Inhibitor
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar K_d value. CC-90002 can be used for the research of hematologic malignancies and solid tumors.

HY-143224B

NCGC00138783 TFA	Inhibitor	99.71%
NCGC00138783 TFA is a selective inhibitor targeting CD47/SIRPα axis, with an IC₅₀ of 50 μM. NCGC00138783 TFA directly blocks the interaction between CD47 and SIRPα axis.

HY-P99175

KWAR 23	Inhibitor	99.80%
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

HY-P991367

ES004	Inhibitor
ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research.

HY-P991366

IBI-397	Inhibitor
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research.

HY-P991057

STI-6643	Inhibitor
STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 displays potent anti-tumor activity with negligible RBC and lymphocyte toxicities. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990033

Anzurstobart	Inhibitor	98.53%
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research.

HY-P99777

Ontorpacept	Inhibitor	99.57%
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity.

HY-P99533

Urabrelimab	Inhibitor	99.47%
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction.

HY-P99026

Lemzoparlimab	Inhibitor	99.31%
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity.

HY-P0144

Thrombospondin-1 (1016-1023) (human, bovine, mouse)	Inhibitor	98.40%
Thrombospondin-1 (1016-1023) (human, bovine, mouse), is the C-terminal end of the native sequence of Thrombospondin-1 (TSP-1), is a CD47 agonist peptide.

HY-P10388

TAX2 peptide	Inhibitor	98.70%
TAX2 peptide is a dodecapeptide based on molecular docking and simulation design, derived from the cell surface receptor CD47 sequence. TAX2 peptide acts as a selective antagonist of TSP-1 (thromboxin-1) interacting with CD47. TAX2 peptide can promote the binding of TSP-1 to CD36, which leads to the destruction of VEGFR2 (vascular endothelial growth factor receptor 2) activation, thereby blocking downstream NO (nitric oxide) signaling, demonstrating anti-angiogenic properties. TAX2 peptide can be used to study angiogenesis and tumor cell interactions in the tumor microenvironment.

HY-P990132

Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410)	Inhibitor
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human CD47/IAP.

HY-P99706

Ligufalimab	Inhibitor	98.81%
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity.

HY-P990858

Anti-CD47 Antibody (B6.H12)	Inhibitor
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD47. The recommend isotype control of Anti-CD47 Antibody (B6.H12): Mouse IgG1 kappa, Isotype Control (HY-P99977).

HY-P990131

Anti-Mouse CD47/IAP Antibody (MIAP301)	Inhibitor
Anti-Mouse CD47/IAP Antibody (MIAP301) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD47/IAP.

HY-P990694

Zeripatamig	Inhibitor	≥99.0%
Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990555

BI-765063	Inhibitor
BI-765063 is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4PE type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.36 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

Name
Email *

	Sorry, but the email address you supplied was invalid.